Adimmune Delivers Strong Q3 Revenue Growth, Driven by Influenza Vaccine

Adimmune Corporation (TPE: 4142) announced on the 6th that the revenue for September 2021 reached TWD 464 million, the second highest monthly revenue at Adimmune. Compared to the corresponding period last year, it reflected a growth of 3.84%. The revenue of Q3 is TWD 753 million, a 22% growth from Q3 last year. 

The revenue for September was mainly driven by the release of quadrivalent influenza vaccine to public sector in Taiwan and Flublok to Protein Science (a Sanofi subsidiary). Starting in October, Adimmune will be focusing on the delivery of quadrivalent influenza vaccines for the domestic needs along with other international orders. It is expected that all product shipments will be completed on schedule before the end of this year, and the growth in revenue is expected to continue through Q4, demonstrating sustained growth in sales performance.

Adimmune expressed that in addition to the current international orders received, from Q3 the company has been expanding its CDMO markets to countries such as Russia, which should contribute to the company’s revenue growth in the coming years.